2014)
- Katayama R, Friboulet L, Koike S, Lockerman E.L, Khan T.M, Gainor J.F, Iafrate A.J, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman J.A, Shaw A.T. “Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor Alectinib” Clinical Cancer Research. 2014;20(22):5686-5696. Available from: https://doi.org/10.1158/1078-0432.ccr-14-1511
- Brown J.B, Nakatsui M, Okuno Y. “Constructing a foundational platform driven by Japan’s K supercomputer for next-generation drug design” Molecular Informatics. 2014;33:732-741. Available from: https://doi.org/10.1002/minf.201400067
- Aoyama A, Katayama R, Oh-hara T, Sato S, Okuno Y, Fujita N. “Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance” Molecular Cancer Therapeutics. 2014;13(12):2978-2990. Available from: https://doi.org/10.1158/1535-7163.mct-14-0462
- Sakaeda T, Kadoyama K, Minami K, Okuno Y. “Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms” Int. J. Med. Sci. 2014;11(5):461-465. Available from: https://doi.org/10.7150/ijms.7967
- Brown J.B, Okuno Y, Marcou G, Varnek A, Horvath D. “Computational chemogenomics: Is it more than inductive transfer?” J. Comput. Aided Mol. Des. 2014;28(6):597-618. Available from: https://doi.org/10.1007/s10822-014-9743-1
- Zannas A.S, Okuno Y, Doraiswamy P.M. “Cholinesterase inhibitors and Pisa syndrome: A pharmacovigilance study” Pharmacotherapy 2014;34(3):272-278. Available from: https://doi.org/10.1002/phar.1359
- Nakazawa S, Sakanaka M, Furuta K, Natsuhara M, Takano H, Tsuchiya S, Okuno Y, Ohtsu H, Nishibori M, Thurmond R.L, Hirasawa N, Nakayama K, Ichikawa A, Sugimoto Y, Tanaka S. “Histamine synthesis is required for granule maturation in murine mast cells” Eur. J. Immunol. 2014;44(1):204-214. Available from: https://doi.org/10.1002/eji.201343838
